The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

Stephen O'Neill, Joan Sweeney, Chris C Patterson, Andrew Menzies-Gow, Rob Niven, Adel H Mansur, Christine Bucknall, Rekha Chaudhuri, Neil C Thomson, Chris E Brightling, Ciaran O'Neill, Liam G Heaney, British Thoracic Society Difficult Asthma Network

Research output: Contribution to journalArticlepeer-review

90 Citations (Scopus)

Abstract

Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalThorax
Volume70
Issue number4
Early online date10 Jun 2014
DOIs
Publication statusPublished - Apr 2015

Keywords

  • Adult
  • Anti-Asthmatic Agents
  • Asthma
  • Body Mass Index
  • Drug Costs
  • Female
  • Forced Expiratory Volume
  • Glucocorticoids
  • Great Britain
  • Health Care Costs
  • Health Services
  • Health Services Research
  • Humans
  • Male
  • Middle Aged
  • Registries
  • State Medicine

Fingerprint Dive into the research topics of 'The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry'. Together they form a unique fingerprint.

Cite this